These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32299907)

  • 1. RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.
    Kellaway SG; Keane P; Kennett E; Bonifer C
    Haematologica; 2021 Jun; 106(6):1569-1580. PubMed ID: 32299907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
    Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
    Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
    Tokita K; Maki K; Mitani K
    Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.
    Loke J; Assi SA; Imperato MR; Ptasinska A; Cauchy P; Grabovska Y; Soria NM; Raghavan M; Delwel HR; Cockerill PN; Heidenreich O; Bonifer C
    Cell Rep; 2017 May; 19(8):1654-1668. PubMed ID: 28538183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
    Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the RUNX1-EVI1 fusion gene in leukemogenesis.
    Maki K; Yamagata T; Mitani K
    Cancer Sci; 2008 Oct; 99(10):1878-83. PubMed ID: 19016745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
    Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
    Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.
    Maki K; Sugita F; Nakamura Y; Sasaki K; Mitani K
    Int J Hematol; 2013 Jan; 97(1):83-91. PubMed ID: 23250858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
    Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
    Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
    Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
    Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
    Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
    Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome.
    Matsuura S; Komeno Y; Stevenson KE; Biggs JR; Lam K; Tang T; Lo MC; Cong X; Yan M; Neuberg DS; Zhang DE
    Blood; 2012 Nov; 120(19):4028-37. PubMed ID: 22919028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
    Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
    Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).
    Sakai I; Tamura T; Narumi H; Uchida N; Yakushijin Y; Hato T; Fujita S; Yasukawa M
    Genes Chromosomes Cancer; 2005 Nov; 44(3):265-70. PubMed ID: 16015645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells.
    Nafria M; Keane P; Ng ES; Stanley EG; Elefanty AG; Bonifer C
    Cell Rep; 2020 May; 31(8):107691. PubMed ID: 32460028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.
    Kohrs N; Kolodziej S; Kuvardina ON; Herglotz J; Yillah J; Herkt S; Piechatzek A; Salinas Riester G; Lingner T; Wichmann C; Bonig H; Seifried E; Platzbecker U; Medyouf H; Grez M; Lausen J
    PLoS Genet; 2016 Mar; 12(3):e1005946. PubMed ID: 26990877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming.
    Kellaway S; Chin PS; Barneh F; Bonifer C; Heidenreich O
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
    Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
    Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.